Business
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well tolerated with a safety profile consistent with that in older children and adultsAtopic dermatitis impacts 1 million children under the age of 2 in the United StatesOnly one other FDA-approved topical non-steroidal anti-inflammatory agent available for this vulnerable population WESTLAKE VILLAGE, Calif
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"image","alt":"Arcutis Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Arcutis Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NsgskJmcmYR2weZA9OX0jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Once-daily ZORYVE cream was well tolerated with a safety profile consistent with that in older children and adults","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Atopic dermatitis impacts 1 million children under the age of 2 in the United States","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Only one other FDA-approved topical non-steroidal anti-inflammatory agent available for this vulnerable population","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":476,"olType":false},{"type":"text","content":"WESTLAKE VILLAGE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication for ZORYVE® (roflumilast) cream 0.05% to include the topical treatment of mild to moderate atopic dermatitis in infants down to 3 months.","length":519,"tagName":"p"},{"type":"text","content":"“Atopic dermatitis often begins within the first year of life, yet treatment options for infants are extremely limited. Parents and caregivers are often faced with difficult decisions around managing these symptoms, including concerns about the long-term use of topical steroids,” said Mercedes E. Gonzalez, MD, medical director of Pediatric Skin Research, LLC and INTEGUMENT-INFANT clinical trial investigator. “Bec...